Quest PharmaTech Inc  

(Public, CVE:QPT)   Watch this stock  
Find more results for CVE:qpt
0.0000 (0.00%)
Sep 30 - Close
CVE data delayed by 15 mins - Disclaimer
Currency in CAD
Range     -
52 week 0.03 - 0.05
Open     -
Vol / Avg. 0.00/54,271.00
Mkt cap 3.14M
P/E     -
Div/yield     -
EPS -0.02
Shares 125.42M
Beta 0.35
Inst. own     -

Key stats and ratios

Q3 (Jul '15) 2015
Net profit margin -505.06% -189.46%
Operating margin -402.42% -176.52%
EBITD margin - -172.62%
Return on average assets -439.28% -295.12%
Return on average equity - -
CDP Score - -


8123 Roper Rd NW
+1-780-4481400 (Phone)
+1-780-4160324 (Fax)

Website links


Quest PharmaTech Inc. (Quest)is a Canada-based biotechnology company committed to the development and commercialization of oncology product candidates. The Company is developing a series of products for the treatment of cancer based on its pipeline of SonoLight compounds, and monoclonal antibodies that target certain tumor antigens that are presented in a variety of cancers. Quest technology platform includes a series of monoclonal antibodies that target several cancer markers such as CA125, MUC1, PSA, CA19.9 and TAG72, and has potential for development in multiple indications. The most advanced of these product candidates is Oregovomab, an anti-CA125 antibody in combination with front-line chemotherapy for the treatment of advanced ovarian cancer that is undergoing a Phase IIb clinical trial in 13 centers in Italy and United States.

Officers and directors

Lorne Meikle Independent Chairman of the Board
Ragupathy Madiyalakan Ph.D. Chief Executive Officer, Director
Pierre Vermette Chief Financial Officer
Thomas Woo Vice President - Product Development
Bin Huang Ph.D. Independent Director
Ian McConnan Independent Director
Paul J. Van Damme CPA Independent Director